Appendix Table C91. Clinical outcomes (outcomes part A), CCB versus BB trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **All-cause Mortality****n/N (%)** | **Cardiovascular Mortality****n/N (%)** | **Myocardial Infarction,****Any n/N (%)** | **Myocardial infarction,****Fatal, n/N (%)** | **Myocardial Infarction,****Nonfatal, n/N (%)** | **Stroke, Any****n/N (%)** |
| **CCB** | **BB** | **CCB** | **BB** | **CCB** | **BB** | **CCB** | **BB** | **CCB** | **BB** | **CCB** | **BB** |
| Bakris, 199663 | 1/18 (5.6) | 4/16 (25.0) | \*NR | \*NR |  |  | \*NR | \*NR |  |  |  |  |
| Wright, 200226;Norris 200627 | 13/217 (6.0) | 38/441 (8.6) | †NR | †NR |  |  |  |  |  |  |  |  |
| Dahlof, 200565  |  |  |  |  |  |  |  |  |  |  |  |  |

CCB = calcium channel blocker; BB = beta blocker
\* Study reported 5 (9.6%) cardiovascular deaths, 4 (7.7%) fatal myocardial infarctions, and 1 (1.9%) fatal stroke, but didn’t indicate to which treatment group these patients had been assigned.
† Study did not report the number of participants with cardiovascular death, but instead the percentage of patients with cardiovascular death per patient year of followup: CCB 0.9%, BB 0.8%.